Abstract
Proactive therapeutic drug monitoring (TDM) measuring infliximab trough levels (IFX TL) annually may be helpful in maintaining therapeutic IFX TL ≥ 3 μg/mL in 85% of patients with inflammatory bowel disease (IBD) and clinical remission on infliximab maintenance therapy.
Introduction
Infliximab (IFX) is a cornerstone biologic therapy for patients with IBD. However, its long-term efficacy is often hampered by pharmacokinetic (PK) failure, where drug levels drop below therapeutic thresholds, eventually leading to a loss of clinical response. To combat this, clinicians utilize therapeutic drug monitoring (TDM). While reactive TDM (testing during a flare) is standard, proactive TDM (regular testing during remission) has shown superior long-term outcomes. The challenge lies in determining the optimal testing frequency that balances clinical safety with medical costs and patient convenience.
Methods
This prospective cohort study was conducted at the Samsung Medical Center in Seoul, South Korea. The study aimed to identify the optimal interval for proactive TDM in stable patients.
The protocol involved checking IFX TL at baseline for patients in clinical remission (defined as HBI < 5 or pMayo < 2). Only patients with a therapeutic baseline IFX TL ($\ge 3 \mu g/mL$) were enrolled. Those below this threshold underwent dose optimization until the target was reached. Following enrollment, IFX TL was measured at every infusion, alongside clinical scores and inflammatory markers.
Patient Cohort
A total of 132 IBD patients treated with scheduled IFX maintenance therapy were assessed for eligibility.
After excluding patients who failed to achieve therapeutic levels despite optimization or withdrew, 103 patients (93 with Crohn’s disease and 10 with ulcerative colitis) were analyzed. The cohort was stratified into two groups based on baseline IFX TL: those with "low-therapeutic" levels (3–5 $\mu g/mL$) and those with "high-therapeutic" levels ($\ge 5 \mu g/mL$).
Key Results
The primary endpoint was PK relapse, defined as two consecutive IFX TL measurements below $3 \mu g/mL$.
- Optimal Monitoring Interval: To maintain an 85% therapeutic persistence rate (where 85% of patients remain above the $3 \mu g/mL$ threshold), the data suggested a testing interval of approximately 13.3 months.
- The "Buffer" Effect: Baseline drug levels were highly predictive of PK stability. Patients in the high-therapeutic group ($\ge 5 \mu g/mL$) had a significantly lower risk of PK relapse (Hazard Ratio: 0.23, $p=0.010$).
- Stratified Persistence: The time to maintain 85% persistence was 10.3 months for the 3–5 $\mu g/mL$ group, compared to 20.2 months for the $\ge 5 \mu g/mL$ group.
- Clinical Correlation: While PK relapse occurred in 18.5% of patients over a median follow-up of 18.5 months, only 7% experienced a clinical or biochemical relapse within 24 months, suggesting that PK failure serves as an early warning sign.
Discussion and Limitations
The study provides empirical evidence that annual TDM is a viable "Goldilocks" strategy for stable IBD patients, catching declining drug levels before clinical symptoms manifest. However, several limitations should be noted. The cohort was heavily skewed toward Crohn’s disease (90.3%), and the results may not be fully generalizable to ulcerative colitis. Additionally, the study was conducted within the specific context of the Korean healthcare system. Future research should focus on larger, more diverse cohorts to refine personalized TDM intervals.
Summary updated